soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 💊 — the active ingredient in Ozempic and Wegovy — became famous as a weight-loss drug, but its credentials turned out to be its most medically significant story. In August Long-term kidney outcomes of semaglutide

CagriSema (semaglutide + cagrilintide), filed by Novo Nordisk in December 2025, achieved 22.7% weight loss in trials and could receive FDA approval in 2026

During AOD 9604 and tirzepatide combination therapy, resistance training becomes even more important because the aggressive fat loss rate means the body will readily catabolize muscle if it is not receiving the stimulus to maintain it

More importantly, these modified GLP-1 analogues have shown hypoglycemic [185, 186] and cardiovascular protective effects [180, 183] in different animal models

Neurovasc Res

The real growth opportunity sits beyond meals, in any category where brands can extract value from fewer eating occasions

As we aim for optimal health, understanding the interactions between medications and supplements is crucial